Summary of Viridian Therapeutics Conference Call Company Overview - **Company**: Viridian Therapeutics (NasdaqCM:VRDN) - **Industry**: Biotechnology, specifically focused on treatments for thyroid eye disease (TED) Key Points and Arguments 1. **Lead Program and Upcoming Milestones**: - Viridian's lead program, veligrotug, is expected to go commercial with a PDUFA date of June 30, 2026, following a successful BLA submission in 2025 [2][3] - The TED market is currently valued at $2 billion with only one product available [3] 2. **Clinical Trials and Data**: - Two Phase 3 readouts are anticipated within the next 12 months, one in Q1 and another in Q2 [2][4] - The first Phase 3 trial focuses on the active form of TED, while the second addresses the chronic form [5] 3. **Regulatory Designations**: - The Breakthrough Therapy designation has facilitated positive interactions with the FDA, enhancing the likelihood of priority review for the BLA [9][11] 4. **Market Readiness**: - The company is nearly 100% launch-ready, having built out its field force and market access teams ahead of the PDUFA date [12][14] 5. **Pricing Strategy**: - Pricing discussions with payers indicate potential parity pricing with Tepezza, allowing for a 10%-15% variance [17] - The pricing strategy will consider the full course of treatment, which consists of five infusions compared to Tepezza's eight [18] 6. **Target Patient Population**: - The current TED patient population is skewed towards active cases, but Viridian aims to capture chronic patients with robust clinical data [19][20] - There are approximately 2,000 core prescribers for IGF-1R therapies, providing a focused target for marketing efforts [22] 7. **Market Expansion with Subcutaneous (SubQ) Program**: - The SubQ program (elegrobart) is expected to expand the market by providing a self-administered option, improving access for patients who cannot easily reach infusion centers [45][46] - The anticipated market split in a mature setting is 70% SubQ and 30% IV [49] 8. **Competitive Landscape**: - Several competitors have faced challenges, with notable programs being terminated or showing mixed results [50][52] - Viridian's trials have been well-received, with high enrollment rates indicating strong patient demand [52] 9. **FcRn Portfolio**: - The FcRn portfolio offers strategic optionality, with two compounds in development that could provide differentiated treatment options in the future [54][55] 10. **TSHR-targeted Program**: - A new TSHR antibody program is in preclinical stages, with potential applications in both TED and Graves' disease [59][60] Additional Important Information - The company has successfully enrolled a significant number of patients in clinical trials, indicating strong interest and demand for IGF-1R therapies [52] - The competitive landscape has shifted favorably for Viridian, with fewer viable competitors in the TED space [53] - The company plans to file an IND for the TSHR program in Q4 2026, indicating ongoing innovation and development [60][64]